AU2021396395A1 - Combination therapies for the treatment of cancer - Google Patents

Combination therapies for the treatment of cancer Download PDF

Info

Publication number
AU2021396395A1
AU2021396395A1 AU2021396395A AU2021396395A AU2021396395A1 AU 2021396395 A1 AU2021396395 A1 AU 2021396395A1 AU 2021396395 A AU2021396395 A AU 2021396395A AU 2021396395 A AU2021396395 A AU 2021396395A AU 2021396395 A1 AU2021396395 A1 AU 2021396395A1
Authority
AU
Australia
Prior art keywords
compound
formula
cancer
egfr
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021396395A
Other languages
English (en)
Other versions
AU2021396395A9 (en
Inventor
Leslie Harris BRAIL
Leenus MARTIN
Robert Field SHOEMAKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasca Inc
Original Assignee
Erasca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasca Inc filed Critical Erasca Inc
Publication of AU2021396395A1 publication Critical patent/AU2021396395A1/en
Publication of AU2021396395A9 publication Critical patent/AU2021396395A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021396395A 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer Abandoned AU2021396395A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124665P 2020-12-11 2020-12-11
US63/124,665 2020-12-11
US202163214718P 2021-06-24 2021-06-24
US63/214,718 2021-06-24
US202163253012P 2021-10-06 2021-10-06
US63/253,012 2021-10-06
US202163277561P 2021-11-09 2021-11-09
US63/277,561 2021-11-09
PCT/US2021/062912 WO2022125962A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2021396395A1 true AU2021396395A1 (en) 2023-07-27
AU2021396395A9 AU2021396395A9 (en) 2024-10-17

Family

ID=81974006

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021396395A Abandoned AU2021396395A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Country Status (7)

Country Link
US (1) US20240050441A1 (https=)
EP (1) EP4259147A4 (https=)
JP (1) JP2023553532A (https=)
KR (1) KR20230154793A (https=)
AU (1) AU2021396395A1 (https=)
CA (1) CA3201657A1 (https=)
WO (1) WO2022125962A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2022125971A1 (en) * 2020-12-11 2022-06-16 Erasca, Inc. Combination therapies for the treatment of cancer
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
WO2023059771A1 (en) * 2021-10-06 2023-04-13 Erasca, Inc. Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
WO2025226830A1 (en) * 2024-04-23 2025-10-30 Erasca, Inc. Shp2 and egfr inhibitors for the treatment of chordoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2601892C2 (ru) * 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US20150273057A1 (en) * 2012-10-25 2015-10-01 Glaxosmithkline Llc Combination
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
JP7542538B2 (ja) * 2018-09-18 2024-08-30 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体
KR20210144844A (ko) * 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
EP4076667A1 (en) * 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20210292330A1 (en) * 2020-02-28 2021-09-23 Erasca, Inc. Pyrrolidine-fused heterocycles

Also Published As

Publication number Publication date
JP2023553532A (ja) 2023-12-21
EP4259147A4 (en) 2024-10-23
AU2021396395A9 (en) 2024-10-17
EP4259147A1 (en) 2023-10-18
WO2022125962A1 (en) 2022-06-16
CA3201657A1 (en) 2022-06-16
KR20230154793A (ko) 2023-11-09
US20240050441A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
US20240293422A1 (en) Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
US20240050441A1 (en) Combination therapies for the treatment of cancer
EP2205242B1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20250195533A1 (en) Combination therapies for the treatment of cancer
US11583577B2 (en) Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
US20170196878A1 (en) Use of cbp/ep300 and bet inhibitors for treatment of cancer
US20240058352A1 (en) Combination therapies for the treatment of cancer
TW202409075A (zh) 用莫蘇妥珠單抗及來那度胺治療先前未經治療的濾泡性淋巴瘤之方法
US20240285624A1 (en) Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
WO2023059771A1 (en) Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
CN117098537A (zh) 用于癌症治疗的联合疗法
HK40103380A (zh) 用於癌症治疗的联合疗法
CN117120449A (zh) 用于癌症治疗的联合疗法
CN117083283A (zh) 用于癌症治疗的联合疗法
US20220304972A1 (en) Combination therapy and biomarker indicating efficacy thereof
HK40103172A (zh) 用於癌症治疗的联合疗法
HK40103377A (zh) 用於癌症治疗的联合疗法

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period